Xiaodong  Wang net worth and biography

Xiaodong Wang Biography and Net Worth

Insider of BeiGene
Xiaodong Wang, Ph.D., is our Co-Founder and has served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang became a member of our Board of Directors in February 2016. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center and B.S. in Biology from Beijing Normal University. Dr. Wang has been a member of the National Academy of Science, USA, since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

What is Xiaodong Wang's net worth?

The estimated net worth of Xiaodong Wang is at least $862.11 million as of January 11th, 2023. Dr. Wang owns 5,512,556 shares of BeiGene stock worth more than $862,108,633 as of March 29th. This net worth evaluation does not reflect any other assets that Dr. Wang may own. Additionally, Dr. Wang receives an annual salary of $250,000.00 as Insider at BeiGene. Learn More about Xiaodong Wang's net worth.

How old is Xiaodong Wang?

Dr. Wang is currently 61 years old. There are 3 older executives and no younger executives at BeiGene. The oldest executive at BeiGene is Dr. Xiaobin Wu Ph.D., President & COO, who is 62 years old. Learn More on Xiaodong Wang's age.

What is Xiaodong Wang's salary?

As the Insider of BeiGene, Ltd., Dr. Wang earns $250,000.00 per year. There are 4 executives that earn more than Dr. Wang. The highest earning executive at BeiGene is Mr. John V. Oyler, Co-Founder, Executive Chairman & CEO, who commands a salary of $2,050,000.00 per year. Learn More on Xiaodong Wang's salary.

How do I contact Xiaodong Wang?

The corporate mailing address for Dr. Wang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Xiaodong Wang's contact information.

Has Xiaodong Wang been buying or selling shares of BeiGene?

Xiaodong Wang has not been actively trading shares of BeiGene during the last ninety days. Most recently, Xiaodong Wang sold 67,635 shares of the business's stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $226.03, for a transaction totalling $15,287,539.05. Learn More on Xiaodong Wang's trading history.

Who are BeiGene's active insiders?

BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.

Are insiders buying or selling shares of BeiGene?

During the last twelve months, insiders at the sold shares 15 times. They sold a total of 2,743,192 shares worth more than $564,897,493.84. The most recent insider tranaction occured on March, 12th when CEO John Oyler sold 37,668 shares worth more than $6,178,305.36. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.

Information on this page was last updated on 3/12/2024.

Xiaodong Wang Insider Trading History at BeiGene

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2023Sell67,635$226.03$15,287,539.05View SEC Filing Icon  
1/11/2023Sell2,500$252.66$631,650.005,512,556View SEC Filing Icon  
1/9/2023Sell900$250.00$225,000.00View SEC Filing Icon  
12/13/2022Sell3,013$211.33$636,737.295,577,556View SEC Filing Icon  
11/15/2022Sell1,987$210.14$417,548.185,629,556View SEC Filing Icon  
5/10/2021Sell3,394$300.46$1,019,761.245,747,271View SEC Filing Icon  
10/16/2020Sell5,000$320.00$1,600,000.007,201,009View SEC Filing Icon  
10/5/2020Sell5,000$300.00$1,500,000.007,201,009View SEC Filing Icon  
9/25/2020Sell5,000$280.42$1,402,100.007,201,009View SEC Filing Icon  
9/17/2020Sell5,000$260.27$1,301,350.007,201,009View SEC Filing Icon  
8/10/2020Sell4,000$211.06$844,240.007,201,009View SEC Filing Icon  
7/7/2020Sell6,000$200.00$1,200,000.007,267,569View SEC Filing Icon  
6/22/2020Sell5,000$181.33$906,650.007,330,580View SEC Filing Icon  
3/4/2020Sell5,000$157.14$785,700.007,395,580View SEC Filing Icon  
11/14/2019Sell8,504$193.31$1,643,908.247,460,580View SEC Filing Icon  
11/4/2019Sell1,000$190.00$190,000.007,585,628View SEC Filing Icon  
11/1/2019Sell1,000$170.00$170,000.007,585,628View SEC Filing Icon  
7/1/2019Sell4,847$126.46$612,951.627,611,628View SEC Filing Icon  
3/1/2019Sell5,000$146.82$734,100.00View SEC Filing Icon  
12/3/2018Sell5,000$152.41$762,050.002,329View SEC Filing Icon  
11/19/2018Sell5,000$124.30$621,500.003,900View SEC Filing Icon  
8/13/2018Sell3,449$158.77$547,597.73View SEC Filing Icon  
7/12/2017Sell20,000$72.44$1,448,800.0016,300View SEC Filing Icon  
6/28/2017Sell35,000$44.95$1,573,250.0026,600View SEC Filing Icon  
6/2/2017Sell5,539$40.00$221,560.0055,000View SEC Filing Icon  
5/4/2017Sell14,461$40.80$590,008.8065,030View SEC Filing Icon  
4/5/2017Sell11,650$36.83$429,069.5081,194View SEC Filing Icon  
3/24/2017Sell38,107$36.96$1,408,434.72116,478View SEC Filing Icon  
3/10/2017Sell36,892$39.89$1,471,621.88150,657View SEC Filing Icon  
2/27/2017Sell38,351$38.19$1,464,624.69194,495View SEC Filing Icon  
See Full Table

Xiaodong Wang Buying and Selling Activity at BeiGene

This chart shows Xiaodong Wang's buying and selling at BeiGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BeiGene Company Overview

BeiGene logo
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Read More

Today's Range

Now: $156.39
Low: $155.09
High: $157.38

50 Day Range

MA: $157.72
Low: $141.80
High: $179.69

2 Week Range

Now: $156.39
Low: $132.95
High: $272.49

Volume

104,128 shs

Average Volume

283,384 shs

Market Capitalization

$14.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62